<DOC>
	<DOCNO>NCT01762280</DOCNO>
	<brief_summary>Famitinib novel oral multitargeted tyrosine kinase inhibitor antitumor antiangiogenic activity . This study design evaluate safety tolerability Famitinib patient solid tumor</brief_summary>
	<brief_title>A Phase I Study Famitinib Malate Patients With Solid Tumor</brief_title>
	<detailed_description>1 . To evaluate safety tolerability Famitinib , maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) . 2 . To determine pharmacokinetic profile Famitinib metabolites . 3 . To assess preliminary antitumor activity . 4 . To determine preliminary dose regimen phase II study .</detailed_description>
	<criteria>Histological confirm advanced metastatic solid tumor，at least one measurable lesion , large 10 mm diameter spiral CT scan ( scan layer ≤ 5 mm ) standard therapy protocol available accord patients'condition sex , age 18 65 ECOG 01 Life expectancy 3 month ALT , AST , TB≤1.5 ( UNL ) , normal serum creatinine level , normal electrolyte correct medication Subjects receive damage cause therapeutic restored , interval six week since last receiving nitroso mitomycin ; 4 week since last receiving radiotherapy , cytotoxic drug surgery Understand agree sign inform consent form . Peripheral neuropathy ≥ Grade 2 ( accord NCICTC 3.0 ) Preexisting uncontrolled hypertension define 140/90 mmHg use single agent therapy , ＞Grade 1 ( NCICTCAE 3.0 ) myocardial ischemia , arrhythmia , cardiac function insufficiency PT , APTT , TT , Fbg abnormal ( PT &gt; 16 , APTT &gt; 43s , TT &gt; 21 , Fbg &lt; 2g/L ) , hemorrhagic tendency receive therapy thrombolysis anticoagulation Active peptic ulcer Previously medication include sunitinib More 4 week since last clinical trial Pregnant lactate woman Women childbearing age take effective contraceptive measure Allergies , know allergy history component drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Famitinib</keyword>
	<keyword>Advanced Solid tumor</keyword>
	<keyword>Phase I</keyword>
</DOC>